Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

More stories below advertisement

Latest Press Releases

Psychedelic Drugs Could Potentially Treat Impending Post-lockdown Mental Health Epidemic
- PR Newswire - PRF - Tue Jun 2, 9:15AM CDT
PR Newswire - PRF - CMTX
Tue Jun 2, 9:15AM CDT
, /PRNewswire/ --  Trials are already underway testing the use of psychedelics such as psilocybin, LSD, ketamine, ecstasy and other currently scheduled drugs to predicted to hit after the lockdown is over. New is also pointing to antidepressants such as Prozac made by (NYSE:LLY) as a potential redirected treatment against the cause of the health crisis itself. Prescriptions for anxiety medication are already , while the potential for a major breakthrough in the form of medical psychedelics is coming from companies such as (NEO:MMED) (OTCQB:MMEDF) (FRA:BGHM),(NYSE:JNJ),(CSE:SHRM) (OTCQB:SHRMF) and (TSX-V:NUMI) (OTC:LKYSD).
Johnson & Johnson to Participate in the Goldman Sachs 41st Annual Global Virtual Healthcare Conference
- PR Newswire - PRF - Thu May 28, 12:44PM CDT
PR Newswire - PRF - CMTX
Thu May 28, 12:44PM CDT
, /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 41st Annual Global Virtual Healthcare Conference on .   Jennifer Taubert, Executive Vice President, Worldwide Chairman Pharmaceuticals will represent the Company in a session scheduled at .
SmarTrend Watching for Potential Pullback in Shares of Johnson&Johnson After 1.58% Gain
- Comtex SmarTrend(R) - Thu May 28, 11:46AM CDT
Comtex SmarTrend(R) - CMTX
Thu May 28, 11:46AM CDT
Johnson&Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $145.83 to a high of $148.10. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $146.44 on volume of 2.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Look for Shares of Johnson&Johnson to Potentially Pullback after Yesterday's 1.58% Rise
- Comtex SmarTrend(R) - Thu May 28, 11:45AM CDT
Comtex SmarTrend(R) - CMTX
Thu May 28, 11:45AM CDT
Johnson&Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $145.83 to a high of $148.10. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $146.44 on volume of 2.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Johnson&Johnson Set to Possibly Rebound After Yesterday's Selloff of 1.14%
- Comtex SmarTrend(R) - Fri May 22, 11:50AM CDT
Comtex SmarTrend(R) - CMTX
Fri May 22, 11:50AM CDT
Johnson&Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $144.24 to a high of $146.29. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $145.82 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Look for Shares of Johnson&Johnson to Potentially Rebound after Yesterday's 1.14% Sell Off
- Comtex SmarTrend(R) - Fri May 22, 11:50AM CDT
Comtex SmarTrend(R) - CMTX
Fri May 22, 11:50AM CDT
Johnson&Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $144.24 to a high of $146.29. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $145.82 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Johnson&Johnson (JNJ) Approaches New Downside Target of $144.33
- Comtex SmarTrend(R) - Fri May 22, 9:08AM CDT
Comtex SmarTrend(R) - CMTX
Fri May 22, 9:08AM CDT
Johnson&Johnson (NYSE:JNJ) has opened bearishly below the pivot of $147.01 today and has reached the first level of support at $145.52. Should the shares continue to fall, the support pivots of $144.33 and $141.65 will be of interest.
Attorney Mark Lanier 'Gratified but Not Yet Satisfied' by Johnson & Johnson Decision to Discontinue Talc-Based Baby Powder
- PR Newswire - PRF - Tue May 19, 9:59PM CDT
PR Newswire - PRF - CMTX
Tue May 19, 9:59PM CDT
, /PRNewswire/ -- , the trial lawyer who earned the largest jury verdict to date on behalf of consumers who have developed cancer from talc-based cosmetics, welcomed an announcement by Johnson & Johnson (NYSE: JNJ) that it would cease manufacturing products containing talc, but he added that more work is ahead for talc victims.
Johnson & Johnson to Provide Webcast Fireside Chat on Clinical Data to be Presented at the American Society of Clinical Oncology and the Janssen Oncology Strategy and Portfolio
- PR Newswire - PRF - Mon May 18, 3:01PM CDT
PR Newswire - PRF - CMTX
Mon May 18, 3:01PM CDT
, /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) will participate in a pre-recorded fireside chat webcast hosted by Cantor Fitzgerald focused on clinical data being presented at the virtual 2020 American Society of Clinical Oncology (ASCO) Annual Meeting. The webcast is intended for investors and other interested parties, and will be available beginning at 8:00a.m ET on .
Johnson&Johnson (JNJ) Approaches New Upside Target of $153.52
- Comtex SmarTrend(R) - Mon May 18, 9:08AM CDT
Comtex SmarTrend(R) - CMTX
Mon May 18, 9:08AM CDT
Johnson&Johnson (NYSE:JNJ) has opened bullishly above the pivot of $148.70 today and has reached the first level of resistance at $151.74. Should the shares continue to rise, the resistance pivots of $153.52 and $158.34 will be of interest.

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies